(October 26, 2020 / Israel21c) The governmental Israel Institute for Biological Research (IIBR) has approval from the Israeli Health Ministry and the Helsinki Committee to begin testing its SARS-CoV-2 vaccine, BriLife, on Nov. 1.
The IIBR has prepared 25,000 doses and has recruited the first volunteers in an 80-person clinical trial, 40 at Hadassah University Medical Center in Jerusalem and 40 at Sheba Medical Center in Ramat Gan.
Each volunteer, aged 18 to 55, will receive an injection (vaccine or placebo). After a few hours of supervision he/she will be discharged and monitored for three weeks for any possible side effects and for the development of antibodies to the virus in response to the vaccine.
The second phase will include extensive safety tests on 960 healthy volunteers, to begin in December in several medical centers across Israel. In this phase, scientists aim to complete vaccine safety precautions, determine effective dosage, and further determine the vaccine’s effectiveness.
The third and final phase is a large-scale trial to test the vaccine’s effectiveness, with the participation of up to 30,000 volunteers. Subject to the success of the first two phases, this phase is scheduled to begin in April or May. If it is successful, the vaccine may be approved for mass use.
On June 21, ISRAEL21c reported that a single dose of the IIBR’s recombinant VSV-∆G-spike vaccine had resulted “in rapid and potent induction of neutralizing antibodies against SARS-CoV-2” in Syrian golden hamsters in a successful preclinical trial. It was also tested successfully in mice, rabbits and pigs, paving the way for human trials.
“Our final goal is 15 million doses for the residents of the State of Israel and for our close neighbors,” said professor Shmuel Shapira, director of the IIBR.
The research institute in Ness Ziona, which is part of the Defense Ministry, has been directing all its efforts in the past few months toward novel coronavirus research.
In collaboration with several partners, the IIBR also is developing an antibody-based COVID-19 treatment and a new method to detect the virus through breath analysis.
Shapira said the name BriLife combines the Hebrew word for health, briut, with “il” for Israel and “life.”
This article was first published by Israel21c.
Support Jewish Journalism
with 2020 Vision
One of the most intriguing stories of the sudden Coronavirus crisis is the role of the internet. With individuals forced into home quarantine, most are turning further online for information, education and social interaction.
JNS's influence and readership are growing exponentially, and our positioning sets us apart. Most Jewish media are advocating increasingly biased progressive political and social agendas. JNS is providing more and more readers with a welcome alternative and an ideological home.
During this crisis, JNS continues working overtime. We are being relied upon to tell the story of this crisis as it affects Israel and the global Jewish community, and explain the extraordinary political developments taking place in parallel.
Our ability to thrive in 2020 and beyond depends on the generosity of committed readers and supporters. Monthly donations in particular go a long way in helping us sustain our operations. We greatly appreciate any contributions you can make during these challenging times. We thank you for your ongoing support and wish you blessings for good health and peace of mind.